logo
Are you the firstborn, middle child or baby of the family? Your place in the birth order affects your health.

Are you the firstborn, middle child or baby of the family? Your place in the birth order affects your health.

Yahoo24-04-2025
While birth order is known to influence people's personality traits and behavior, whether you're the cautious first-born or the risk-taking youngest child, that's not the only way it affects your life. Research suggests it may also affect some aspects of your health, including your immune system, obesity risk, anxiety levels and more. 'Although health outcomes are influenced by myriad factors, an individual's personality traits, coping mechanisms and stress management, which greatly impact overall well-being, are layered by the intricate role of birth order,' Dr. Michael Valdez, medical director of Detox California, tells Yahoo Life.
Whether you're the oldest child, the youngest or are right in the middle (and even if you're an only child), here are some of the surprising ways birth order can have an impact on your physical and mental health.
First-born children tend to be responsible, or rule followers. They often take on the caretaking role among their siblings. They can be prone to worry and are often seen as mature for their age. They are known to be comfortable taking charge. One study found that CEOs are more likely to be the first-born child. Another showed they are more likely to get higher education and make more money than their younger siblings.
But being first-born doesn't necessarily mean an easy life start. One study found that firstborns were more likely to be born preterm and with lower birth weight compared to their later-born siblings. However, this gets balanced out because parents tend to be more attentive with their firstborn when it comes to doctor's visits and preventive care than their subsequent children — specifically, the study authors found that 'earlier-born children are more likely to participate in preventive medical screenings, their vaccine uptake rates are higher and they see their general practitioner (GP) or pediatrician more often.' Researchers say that, as parents have more children, this may change likely due to waning resources, including time and money.
Beyond the physical health aspects, Alyson Curtis, a New York-based therapist and founder of Attuned Therapy, says that because they're born first, the oldest sibling is often 'parentified,' or pushed into a parent-like role. For girls, there's even a specific term for this — eldest daughter syndrome, which describes the disproportionate responsibility often given to the oldest girl in the family.
'Essentially, the eldest child grows up too fast as a form of survival,' Curtis tells Yahoo Life. 'They learned at a young age that taking care of others is where their self-worth lies since that is what their caregiver valued in them.'
Because of this, older siblings may end up being more 'conscientious or careful, possibly because of the higher expectations placed on them, and may be more proactive in managing their health,' Claudia Giolitti-Wright, founder of Psychotherapy for Young Women, tells Yahoo Life.
But this kind of upbringing can have 'dangerous implications on their mental health,' says Curtis.
A report from Epic Research published in 2024 found that the oldest children were 48% more likely to have anxiety and 35% more likely to have depression than those who came later in the birth order.
Ah, the middle child. If you are one, then you already know the struggle of being overlooked and forgotten. There's even a term for it: middle child syndrome.
Sandwiched between the responsible eldest and the free-spirited youngest, middle children tend to be the peacemaking mediators of the family. While they can be people pleasers, they are also known to be rebels who try to carve out their own path. Research shows middle children engage in riskier behavior than their older siblings.
It might be a tough place in the birth order, but being the in-between also has its benefits. A large study published in February showed that middle children ranked highest in honesty, kindness and cooperation.
Still, Giolitti-Wright says she has seen patterns of self-silencing and feeling overlooked in middle children. They 'tend to ignore their needs because it wasn't ever about them.'
This can affect mental well-being, sometimes manifesting as anxiety or depression, especially if the middle child's role in the family wasn't clearly defined or validated, adds Giolitti-Wright.
When it comes to physical health, middle children tend to have better immune systems than the oldest because of the early exposure to germs.
Youngest children are often seen as charming free spirits. As the babies of the family, no matter their age, they are generally given more leniency than their older siblings. They are known to be fun, rebellious risk-takers.
The good news for the youngest ones is that they, just like middle children, tend to have better immunity than their oldest sibling thanks to the germs they are exposed to from the get-go, early and often. This is known as the Hygiene Hypothesis. One paper found that younger siblings are less likely to have asthma and allergies than their oldest sibling, while other research suggests that having older siblings is associated with a lower risk of food allergies.
Still, while the oldest sibling tends to have worse health outcomes at birth, that role switches as kids get older, with research showing that younger siblings are more likely to have hospitalizations because of risky behavior, including accidental injuries and drug use.
While youngest siblings are often indulged for being 'the baby' or the "protected" one, they 'might receive less one-on-one medical attention simply because parents are stretched thinner or less anxious than they were with their first child,' says Giolitti-Wright.
When it comes to mental health, Curtis says younger siblings can be prone to struggles with self-esteem and self-efficacy. 'Essentially, the pervasive dynamic of 'coming last' to older siblings leads to a reduced sense of one's own abilities,' she says. 'When you consistently can't influence outcomes due to the developmental disadvantage of being last in the birth order, you adapt by 'going with the flow.''
A younger sibling may go on to be an adult who speaks up less, continues Curtis, believing that their opinion doesn't matter as much because it didn't when they were learning how the world worked. 'A self-fulfilling prophecy is then enacted over and over again, creating a vicious cycle, wherein the individual doesn't feel very powerful in their own life. … These types of thoughts have the capacity to alter one's entire life, from what profession they choose to what kind of partner they marry,' says Curtis.
Are only children really "lonely onlys"? The idea of being an only child has strangely gotten a bad reputation in the past, even gaining the term 'only child syndrome.' This refers to the idea that children who do not have siblings are bossy, spoiled, selfish and lack coping skills. But there isn't much evidence to support this claim.
'One of the benefits I often see in both research and my own clinical work is that only children tend to be highly verbal, mature for their age and comfortable in adult spaces,' says Giolitti-Wright. 'They're often great at entertaining themselves, thinking creatively and developing a strong sense of identity because they've had a lot of solo time and adult interaction growing up.'
Still, if an only child comes from a dysfunctional household, Curtis says this is where things can get tricky. 'I … see in my practice how only children take a greater hit coming from households with complex trauma than their counterparts who had siblings. … Siblings can be a life vest for any intense pressure or dysfunction the parents are knowingly or unknowingly putting on the children.'
Like first-born children, research shows only children are more prone to anxiety and depression. 'Only children may have better access to resources but might also carry higher pressure to excel,' says Giolitti-Wright.
When it comes to physical health, research suggests there's a link between only children (and last-born children) and a higher risk of obesity in childhood and adulthood. In another study, researchers found that only and last-born children are more likely to be overweight or obese if their mothers tended to discourage them from eating and were less likely to praise them during meals.
While birth order can influence a person's life, there are no absolutes, Amy McCready, founder of Positive Parenting Solutions, tells Yahoo Life. 'As parents, we have tremendous power to help our kids avoid falling into those common stereotypes through the way we interact with them.'
When it comes to their kids, McCready says it's important for parents to try and avoid labels and comparisons, which can pigeonhole kids into roles in which they feel stuck, even into adulthood. Instead, celebrate individual strengths.
Next, check in with them. 'It's not just what we do, it's how our kids interpret it,' McCready says. She suggests asking: 'How do you feel about the jobs we each have in the family?' and 'Do you ever feel like I expect more from you than your siblings?'
For families with multiple children, it's important to 'prioritize one-on-one time,' says McCready. 'Even just 10 or 15 minutes fosters deep emotional connection and helps each child feel truly seen, heard and valued. Because it's one-on-one, your child doesn't have to compete with siblings for your attention — they get you all to themselves, reinforcing their sense of belonging and significance, no matter their birth order.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Navigating ADHICS Compliance: How MIT Consultants is Shaping Cybersecurity Standards in UAE Healthcare
Navigating ADHICS Compliance: How MIT Consultants is Shaping Cybersecurity Standards in UAE Healthcare

Yahoo

time2 hours ago

  • Yahoo

Navigating ADHICS Compliance: How MIT Consultants is Shaping Cybersecurity Standards in UAE Healthcare

Dubai, UAE,, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As UAE healthcare and financial institutions race to meet stringent ADHICS regulations, MIT Consultants emerges as a trusted advisor, guiding enterprises toward robust compliance through tailored cybersecurity solutions. The cybersecurity landscape in the UAE has dramatically evolved, with healthcare and financial institutions facing heightened regulatory demands under the Abu Dhabi Healthcare Information and Cyber Security Standards (ADHICS). Recent high-profile data breaches and cyber threats have highlighted the urgent need for organizations to comply fully with these standards, protecting sensitive patient and financial information. As organizations scramble to adapt, MIT Consultants, a Dubai-based cybersecurity advisory and solutions reseller, is becoming a pivotal player in assisting healthcare and financial institutions in navigating the complexities of ADHICS compliance. Expert Advisors, Tailored Solutions MIT Consultants differentiates itself through its vendor-neutral advisory approach, ensuring that the solutions recommended are best suited to each organization's specific operational and compliance needs. Rather than advocating for a particular product, the firm's cybersecurity experts thoroughly analyze an institution's existing infrastructure, identify vulnerabilities, and align their recommendations precisely with ADHICS requirements. "Our role goes beyond mere reselling of cybersecurity solutions," says Mohamed Moussous, CEO of MIT Consultants. "We see ourselves as strategic partners. Our clients benefit from our ability to pinpoint precisely what's needed to achieve compliance efficiently and securely." Addressing Critical Cybersecurity Needs Healthcare and financial institutions face particular vulnerabilities—ransomware, phishing attacks, insider threats—all of which ADHICS compliance seeks to mitigate through rigorous cybersecurity measures. MIT Consultants addresses these threats by implementing robust Privileged Access Management (PAM), real-time threat detection systems, patch management processes, and secure information management strategies tailored specifically to ADHICS regulations. Real-World Successes MIT Consultants has successfully guided numerous institutions through ADHICS compliance by identifying gaps, providing detailed roadmaps, and recommending integrated solutions from global cybersecurity vendors. Their expertise ensures minimal operational disruption while achieving full regulatory adherence, ultimately safeguarding institutions from both cyber threats and potential regulatory penalties. "With our deep understanding of the UAE cybersecurity landscape, we provide not just technical solutions but peace of mind," adds Moussous. "Our clients trust us because we have their best interests at heart, which is compliance, security, and operational efficiency." A Strategic Advantage In an environment where regulatory compliance and cybersecurity intersect critically, MIT Consultants offers UAE healthcare and financial institutions a significant strategic advantage. By entrusting compliance initiatives to specialized cybersecurity advisors, organizations can stay ahead of threats, ensure adherence to regulations, and maintain a secure operational environment. As ADHICS continues to shape the future of cybersecurity compliance in the UAE, MIT Consultants stands out as an indispensable ally, turning complex regulatory challenges into clear, actionable strategies. Mohamed Moussous, CEO of MIT ConsultantsIRIS BAY - Business Bay Dubai Website: of the Group : CONTACT: mmoussous@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Northwell's Staten Island University Hospital Performs First U.S. Procedure With New BioHealx Device for Complex Anal Fistulas
Northwell's Staten Island University Hospital Performs First U.S. Procedure With New BioHealx Device for Complex Anal Fistulas

Business Wire

time2 hours ago

  • Business Wire

Northwell's Staten Island University Hospital Performs First U.S. Procedure With New BioHealx Device for Complex Anal Fistulas

STATEN ISLAND, N.Y.--(BUSINESS WIRE)--Northwell's Staten Island University Hospital (SIUH) is the first medical center in the United States to perform surgery using the newly FDA-cleared BioHealx ®Anal Fistula Device - offering new hope to patients suffering from complex and often debilitating anal fistulas. The procedures were performed by colorectal surgeons Poppy Addison, MD, and Giovanni Bonomo, MD, director of colorectal surgery. The BioHealx device, developed by Irish-based Signum Surgical, represents a significant advancement in the treatment of complex anal fistulas, notoriously difficult to treat with current surgical options. The minimally invasive, absorbable implant is designed to close fistula tract as it traverses the anal sphincter complex, without involving any significant disruption of the anorectal anatomy. Early European data demonstrated an 84% success rate, far exceeding traditional approaches that often have success rates closer to 60% and are associated with the need for multiple procedures to finally achieve healing. 'Historically, these surgeries have been long, complex, traumatic to the anorectum and carried the risk of recurrence and incontinence,' said Dr. Bonomo. 'The BioHealx device is intuitive, efficient, and minimizes surgical trauma. If we can replicate the European outcomes, this could set a new standard of care in fistula treatment.' Approximately, 90,000 complex anal fistula procedures are performed yearly. These fistulas predominantly affect men between ages 18 and 50, and disrupts their quality of life due to anal pain, foul-smelling drainage, and recurrent infection. Fistulas can recur even after what appears to be healing at the skin level due to persistence of the transsphincteric fistula tract, and many patients undergo multiple interventions before finding relief. 'Rectal fistulas are under-researched and have lacked a reliable, standardized solution,' said Dr. Addison. 'This device has the potential to optimize care, shorten recovery, and reduce recurrence, all while preserving continence, which is a critical concern for our patients.' Before surgery, a seton drain is placed to help mature the fistula tract and to provide for clear identification of the internal fistula opening. During the BioHealx procedure, the seton is removed, the tract is brushed clean, and a small flap is created to expose the internal sphincter at the location of internal opening. The corkscrew-shaped BioHealx implant is then inserted to compress the tissue around the fistula tract as it traverses the width of the sphincter complex to deliver primary healing by direct tissue apposition. The flap is closed over the internal opening and internal anal sphincter, while the outer tract is partially opened for optimal drainage - all without damaging the sphincter muscle nor disrupting the anal canal. The implant itself is made from bioabsorbable polylactic glycolic acid and naturally dissolves in the body within six to twelve months, leaving no permanent material behind. The inspiration for the BioHealx device dates back to 2013 when engineers Eoin Bambury and Moshe Zilversmit, co-founders of Signum Surgical, met during a government-sponsored fellowship in Ireland. After observing the repeated failure of traditional surgeries to treat anal fistulas, often requiring four or more operations, they launched Signum Surgical in 2016 to develop a better solution. 'The key was identifying the failure of primary healing of the transsphincteric portion of the fistula tract as the root cause of surgical failure,' said Bambury. 'Our goal was to close it effectively without damaging the anal canal nor the anal sphincter. After years of research, clinical trials, and design refinement, we're proud to see our work helping patients here in the U.S.' SIUH's successful completion of the first U.S. procedures using the BioHealx device represents a critical milestone in the adoption of innovative, patient-centered technology across Northwell Health. 'Northwell has always championed advanced technologies that improve outcomes and quality of life,' said Dr. Bonomo. 'This is the kind of breakthrough that can change how we treat complex anal fistulas nationwide.' Drs. Bonomo and Addison will continue evaluating patient outcomes to help guide future adoption and research of the BioHealx procedure. With a shorter learning curve than many other surgical techniques, the team believes the procedure can be easily adopted across the entire system. 'We're incredibly optimistic,' said Dr. Addison. 'This device doesn't burn any bridges - it's safe, effective, and easy to use. If it doesn't work, patients still have all their future options with essentially normal anorectal anatomy. But if it does, it can spare them years of painful, frustrating treatments.'

Donald Trump Threatens 250% Tariff on Pharmaceuticals
Donald Trump Threatens 250% Tariff on Pharmaceuticals

Newsweek

time2 hours ago

  • Newsweek

Donald Trump Threatens 250% Tariff on Pharmaceuticals

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump has said that tariffs on pharmaceutical imports could eventually reach up to 250 percent, as his administration works to lower prescription prices for Americans. During an interview with CNBC on Tuesday, the president said he will initially impose a "small tariff on pharmaceuticals," which will rise to 150 percent "in one year, one and a half years maximum," before then eventually jumping to 250 percent. Newsweek reached out to the White House via email for comment. Why It Matters The United States imports a significant amount of pharmaceuticals each year—over $200 billion in 2024, according to the Observatory of Economic Complexity. Should Trump follow through on ramping up these duties, the highest he has threatened on the industry to date, experts believe this could result in significant increases to drug prices in the U.S. However, some health policy experts told Newsweek this could also help rebalance the global drug supply chain to better favor American customers. What To Know Trump said that the tariffs are intended to encourage pharmaceutical companies to move their operations to the U.S.—"because we want pharmaceuticals made in our country"—and to minimize reliance on Europe. He had previously threatened to place 200 percent tariffs on pharmaceuticals in July, but said he would give the industry time before this change came into effect. Trump's threats of pharmaceutical tariffs have raised concerns among experts that these could lead to increased costs and medication shortages in the U.S. In April, the UNC Center for the Business of Health published a report warning that these effects would be especially significant for generic drugs, which are more likely to be imported and operate on lower profit margins than brand-name medications. "A 250 percent tariff on pharmaceuticals would have a significant impact on drug prices," said health economist Jeromie Ballreich. Ballreich told Newsweek that, for branded pharmaceuticals, higher costs from the tariffs will be "passed on to consumers and most likely will be indirect through higher prescription drug insurance premiums." Major pharmaceutical companies across the world saw their shares fall on Wednesday following Trump's announcement. England-based AstraZeneca was down by 1.1 percent, Indiana-based Eli Lilly by 2.3 percent, and Germany-based Bayer AG by nearly 10 percent as of 11:20 ET. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, 2025. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, latest threat comes as the industry braces for the outcome of an ongoing probe by the Commerce Department into the national security implications of America's medicinal imports. The investigation was launched in April by Commerce Secretary Howard Lutnick under Section 232 of the 1962 Trade Expansion Act. Trump did not provide many specifics, such as whether certain classes of pharmaceuticals would be exempt, beyond stating that these tariffs are separate from the country-specific duties that came into effect last week. However, the announcement appears to contradict the terms of the European Union deal struck in July, which the European Commission president said placed a 15-percent tariff "ceiling" on multiple sectors, including pharmaceuticals. Experts had already warned that the 15 percent tariff outlined in the EU trade deal could end up costing the pharmaceutical industry billions. The cost implications could also be seen as conflicting with the administration's separate attempts to lower the price of prescription drugs. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, 2025. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, May, Trump signed an executive order directing the Secretary of Commerce and U.S. Trade Representative to "ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States." It also proposed that the U.S. be given Most-Favored-Nation (MFN) status, which would require drug companies to offer Americans the same lowest price that drugs are sold for in other countries. Trump followed this up by sending letters to 17 of the world's largest pharmaceutical companies on July 31, outlining steps they must take within 60 days to lower prescription prices for U.S. customers. These include extending MFN pricing to Medicaid, guaranteeing MFN pricing for new medications and negotiating "harder with foreign freeloading nations." The letters also call on the companies to expand direct-to-consumer distribution models to ensure customers "get the same low MFN prices that manufacturers already offer to third-party payers." "At face value, these tariffs are contradictory to his efforts to lower domestic prices," Ballreich told Newsweek. "However, if the tariffs are used as a threat to get drug companies to comply to his administration's [executive orders], including the recent letters to pharmaceutical CEOs, then I think we could see some changes to the pharmaceutical market, which will lower domestic drug prices." Several drugmakers, including Eli Lilly, AstraZeneca and Johnson & Johnson, have also pledged to expand their U.S. manufacturing presence. Prior to the letters being sent, but amid this pressure from the administration, a number had also announced they would be reducing some U.S. drug prices. Health policy analyst Mariana Socal warned that beyond potential cost implications, the tariffs could significantly disrupt the drug development pipeline, potentially jeopardizing the release of new medications. "Aside from the problem of added costs, the uncertainty introduced by tariff policies is detrimental in and of itself to the pharmaceutical market," she told Newsweek, noting that only around one in 10,000 investigated compounds make it to pharmacy shelves, and only do so after decades of work. "Any added uncertainty is likely to be detrimental to this industry, including disincentivizing investors from supporting this industry and pharmaceutical manufacturers from continuing to look for cures," she said. What People Are Saying Health economist Jeromie Ballreich told Newsweek: "This tariff could really disrupt the U.S. prescription drug market, especially the Medicare part D market, where the party plans will be on the hook for the higher price prices and result in significant premium increases to offset these higher prices. Given that, I don't think it's likely that this massive tariff will occur, but rather is a threat to force companies to find solutions based on the executive orders and his recent letters to pharmaceutical CEOs." Mariana Socal, an associate professor at the Johns Hopkins Bloomberg School of Public Health, told Newsweek: "It is critical to continue to identify solutions to lower drug prices in America and improve drug affordability for Americans. However, it is unclear how tariffs would advance affordability. On the opposite, tariffs can be understood as a hidden tax." "In the short term, the likelihood that added costs from tariffs will be passed through to consumers can be reduced by existing contractual agreements with supply chain participants such as distributors and group purchasing organizations, which can protect buyers from price increases for 1-3 years," she added. "However, even if the added cost of tariffs would not necessarily be passed-through to patients in the short term, it could raise costs in the long run." What Happens Next On Sunday, Trump said he would be announcing tariffs on the industry "within the next week or so."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store